EASL 2019 – Novo buys into Gilead’s Nash combo plan
Today’s deal will see the companies take a triple combination into clinical trials.
Alnylam swaps Regeneron for Sanofi
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
Bayer holds its nerve as patent cliff approaches
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Sanofi doubles down on Biontech
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
Novo sets up antisense challenge with Staten deal
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
Astrazeneca asset swap kickstarts Innate's independence
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
Amicus muscles in on Pompe gene therapy chase
As data on Amicus Therapeutics' clinical-stage Pompe disease candidate roll in, the group locks up preclinical gene therapy assets.
Novo casts its net wider but shrinks in the process
The company’s plan to cut jobs and look at external deals could be a sign that it is becoming more like other big pharmas.
Looking for new mechanisms to cure hepatitis B
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.